Certain Coamoxiclav Products, Potassium Clavulanate Products, and Other Products Derived From Clavulanic Acid; Notice of Investigation

Streszczenie

Notice is hereby given that a complaint was filed with the U.S. International Trade Commission on August 9, 2002, under section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, on behalf of GlaxoSmithKline plc of the United Kingdom and SmithKlineBeecham Corp. d/b/a GlaxoSmithKline of Philadelphia, Pennsylvania. A supplement to the complaint was filed on August 28, 2002. The complaint, as supplemented, alleges violations of section 337 in the importation into the United States, the sale for importation, and the sale within the United States after importation of certain coamoxiclav products, potassium clavulanate products, and other products derived from clavulanic acid by reason of misappropriation of trade secrets and unfair competition. The complaint further alleges that there exists in the United States an industry as required by subsection (a)(1)(A) of section 337. The complainants request that the Commission institute an investigation and, after the investigation, issue a permanent exclusion order and a permanent cease and desist order.